Small Cap Wrap: Uber acquisition for Ubisense, Clarity is crystal clear and great sounds from Chime

Wednesday, Oct 12 2011 by
1
Small Cap Wrap Uber acquisition for Ubisense Clarity is crystal clear and great sounds from Chime

The FTSE 100 opened last week at 5,000 points and closed at 5,300, whilst the AIM All Share closed the week in line with where it opened- at 695 points. The markets have continued with a lack of predictability, though this has somewhat been eased by the voting of Eurozone states on measures to increase the powers of the Eurozone bailout fund (increasing the funds’ capacity to EUR 440bn) in order to help tackle the European financial crisis - 16 of 17 member states have given approval, with Slovakia yet to vote. The week ahead sees British Retail Consortium retail figures being released, together with unemployment figures (forecast to hit 8 per cent) and average earnings, and the purchase of £5bn of gilts by the BoE as part of its quantitative easing programme (QE2).

AdEPT Telecom ( ADT 31.5p / £6.64m)

Adept Telecom (LON:ADT) announced this week that it has been awarded a 3 year Voice over IP migration contract with an existing customer worth an estimated revenue of £2.5m over the life of the contract with one of UK’s largest wholesalers. This contract covers 395 sites across 5 subsidiaries. Ian Fishwick, CEO said that this is one of the largest VoIP contracts placed so far in the UK, and an initial pilot covering 90 sites is anticipated to be followed by a phased roll-out of the other 300 sites.

Angle (LON:AGL) (AGL 59.5p/£21.1m)

Since the announcement that Parsortix's cell separation device can capture cancer cells added to blood (announced on 28 September), ANGLE has increased its holding in Parsortix Inc to 90 per cent. ANGLE completed an equity fundraising to raise €1.25m in July 2011, 80 per cent of which has been allocated to Parsortix to fund the definitive validation of its initial findings (now complete), to optimise the separation device and commence beta testing with cancer clinics. ANGLE has agreed the terms for this further investment in Parsortix and, in addition, has acquired part of the holding of George Hvichia, the Chief Technical Officer and the original inventor of Parsortix's separation device. Following the acquisition of part of Mr Hvichia's shareholding, ANGLE's holding in Parsortix has immediately increased to 90 per cent allowing ANGLE to ensure Parsortix is a qualifying subsidiary for the purposes of deploying funds raised under the EIS and VCT schemes. Mr Hvichia has…

Unlock this article instantly by logging into your account

Don’t have an account? Register for free and we’ll get out your way

Disclaimer:  

This document should not be relied upon as being an impartial or objective assessment of the subject matter and is not deemed to be "independent research" for the purposes of the Financial Services Authority (FSA) rules. As a consequence the research (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research (although Hybridan does impose restrictions on personal account dealing in the run up to publishing research as set out in our Conflicts of Interest Policy).

The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual partners and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document.

This document has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. The information contained herein is based on materials and sources that we believe to be reliable, however, Hybridan LLP makes no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Opinions expressed are our current opinions as of the date appearing on this material only. Any opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. None of Hybridan LLP, its affiliates or employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from any use of this document.

In the UK, this report is directed at and is for distribution only to persons who (i) fall within Article 19(1) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties of Hybridan LLP (all such persons together being referred to as "relevant persons"). This report must not be acted on or relied up on by persons in the UK who are not relevant persons.

Neither this report nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Investments in general involve some degree of risk, including the risk of capital loss. The services, securities and investments discussed in this document may not be available to or suitable for all investors. Investors should make their own investment decisions based upon their own financial objectives and financial resources and, if in any doubt, should seek advice from an investment advisor. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. Where investment is made in currencies other than the investor?s base currency, movements in exchange rates will have an effect on the value, either favourable or unfavourable. Levels and bases for taxation may change. When Hybridan LLP comments on AIM or PLUS Markets shares investors should be aware that because the rules for those markets are less demanding than the Official List of the London Stock Exchange the risks are higher. Furthermore, the marketability of these shares is often restricted.

Hybridan LLP and/or its associated companies may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the partners, directors and employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this material may be duplicated in any form or by any means. Neither should any of this material be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is Authorised and Regulated by the Financial Services Authority and is a member of the London Stock Exchange.


Hybridan LLP
29 Throgmorton Street, London EC2N 2AT

If you would like to receive other research reports from Hybridan, or would like to unsubscribe, please e- mail research@hybridan.com, title e-mail "research reports" or "unsubscribe me" Hybridan LLP is authorised and regulated by the Financial Services Authority Member of the London Stock Exchange


Do you like this Post?
Yes
No
1 thumb up
0 thumbs down
Share this post with friends



AdEPT Technology Group plc, formerly AdEPT Telecom plc, is engaged in providing managed services for information technology (IT), unified communications, connectivity and voice to over 100 Councils, NHS Trusts and other government bodies. The Company's segments are fixed line services (being calls and line rental services) and managed services (which are data connectivity, hardware services, IP telephony, support and maintenance services). It is engaged in the provision of voice and data communication services to both domestic and business customers. The Company offers technical and commercial options for onsite and cloud-based telephony. The Company serves approximately 20,000 commercial customers including worldwide and nationwide brand names. more »

LSE Price
347p
Change
 
Mkt Cap (£m)
82.2
P/E (fwd)
10.9
Yield (fwd)
2.9

Arbuthnot Banking Group PLC is a United Kingdom-based company involved in banking and financial services. The Company operates through three segments: UK Private Banking (Arbuthnot Latham & Co., Limited), Retail Banking and Group Centre. The Retail banking segment incorporates household cash management, personal lending and banking and insurance services. The UK Private banking segment incorporates private banking and wealth management. The Group Centre segment includes Arbuthnot Banking Group (ABG) Group Center management. Private Banking comprises current accounts, deposit accounts, loans, overdrafts and foreign exchange. Its discretionary investment management service comprises asset management and developing tailored investment strategies. more »

LSE Price
1295p
Change
-1.2%
Mkt Cap (£m)
192.8
P/E (fwd)
14.3
Yield (fwd)
3.0

Immunodiagnostic Systems Holdings PLC is a specialist in vitro diagnostic solution provider to the clinical laboratory market. The Company develops, manufactures and markets immunoassays and automated immunoanalyser technologies. It operates through three business segments: Automated IVD, Manual IVD, and Licensing & Technology. The automated IVD business consists of 25-OH Vitamin D, specialties and instrument sales. The automated IVD business also consists of the sale or placement of its IDS-iSYS instrument, in addition to selling automated assays and consumables for use in these instruments. The Manual IVD business sells manual assays, radio immunoassays (RIA) and ELISA kits (EIA) to labs. Its assay development is focused in the clinical areas, such as calcium metabolism, bone metabolism, chronic kidney disease, hypertension, fertility and growth. Its subsidiaries include Immunodiagnostic Systems Limited, Immunodiagnostic Systems Nordic A/S and Immunodiagnostic Systems France SAS. more »

LSE Price
187.5p
Change
 
Mkt Cap (£m)
54.0
P/E (fwd)
46.3
Yield (fwd)
1.2



  Is LON:ADT fundamentally strong or weak? Find out More »


What's your view on this article? Log In to Comment Now

You can track all @StockoChat comments via Twitter


About Hybridan

Hybridan

Hybridan is a corporate broker and PLUS markets corporate advisor specialising in fundraising, research and after-market support for small and micro cap companies. We utilise our market knowledge to provide creative financing solutions and strong after-market support. We build long term durable relationships with companies and investors, for the benefit of both. This long term approach, coupled with a high degree of selectivity, yields investments that outperform the market. more »



Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis